The DOI matches its Crossref record; 529 of the 529 references it cites were found in a registry or an index.
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 1: Update 2012 on the acute treatment of schizophrenia and the management of treatment resistance
Abstract
These updated guidelines are based on a first edition of the World Federation of Societies of Biological Psychiatry Guidelines for Biological Treatment of Schizophrenia published in 2005. For this 2012 revision, all available publications pertaining to the biological treatment of schizophrenia were reviewed systematically to allow for an evidence-based update. These guidelines provide evidence-based practice recommendations that are clinically and scientifically meaningful and these guidelines are intended to be used by all physicians diagnosing and treating people suffering from schizophrenia. Based on the first version of these guidelines, a systematic review of the MEDLINE/PUBMED database and the Cochrane Library, in addition to data extraction from national treatment guidelines, has been performed for this update. The identified literature was evaluated with respect to the strength of evidence for its efficacy and then categorised into six levels of evidence (A-F; Bandelow et al. 2008b, World J Biol Psychiatry 9:242). This first part of the updated guidelines covers the general descriptions of antipsychotics and their side effects, the biological treatment of acute schizophrenia and the management of treatment-resistant schizophrenia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 401–529 of 529
Further evidence of a dose-response threshold for haloperidol in psychosis
Stone, C. K., Garve, D. L., Griffith, J., Hirschowitz, J., & Bennett, J. E. (1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.8.1210 · Cited by 54
The Scottish First Episode Schizophrenia Study: II. Treatment: Pimozide Versus Flupenthixol
(1987) · The British Journal of Psychiatry · doi:10.1192/bjp.150.3.334 · Cited by 54
Gallhofer, B., Jaanson, P., Mittoux, A., Tanghøj, P., Lis, S., & Krieger, S. (2007) · Pharmacopsychiatry · doi:10.1055/s-2007-990291 · Cited by 53
Kim, J. H., Yim, S. J., & Nam, J. H. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.10.001 · Cited by 53
Zotepine vs. haloperidol in paranoid schizophrenia: a double-blind trial.
Ww, F., Barnas, C., Stuppäck, C., Unterweger, B., Miller, C., & Hinterhuber, H. (1989) · PubMed · Cited by 53
New generation antipsychotics for first episode schizophrenia
Hamann, J., Kissling, W., Leucht, S., & Rummel‐Kluge, C. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004410 · Cited by 52
(2009) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9780890423929 · Cited by 52
Riedel, M. J., Schennach-Wolff, R., Musil, R., Dehning, S., Cerovecki, A., Opgen-Rhein, M., Matz, J., Seemüller, F., Obermeier, M., Engel, R. R., et al. (2010) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.1101 · Cited by 50
Self-citationZhang, X.-Y., Zhou, D. F., Cao, L., Zhang, P.-Y., Wu, G. Y., & Shen, Y. (2001) · International Clinical Psychopharmacology · doi:10.1097/00004850-200111000-00002 · Cited by 50
Effectiveness of second-generation antipsychotics with acute-phase schizophrenia
Hatta, K., Sato, K., Hamakawa, H., Takebayashi, H., Kimura, N., Ochi, S., Sudo, Y., Asukai, N., Nakamura, H., Usui, C., et al. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2009.05.030 · Cited by 50
Aggarwal, N. K., Sernyak, M. J., & Rosenheck, R. A. (2012) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31825244f6 · Cited by 50
Citrome, L., Shope, C. B., Nolan, K. A., Czobor, P., & Volavka, J. (2007) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e3281c61baf · Cited by 49
Combined Treatment of Schizophrenic Psychoses with Haloperidol and Valproate
Dose, M., Hellweg, R., Yassouridis, A., Theison, M., & Emrich, H. M. (1998) · Pharmacopsychiatry · doi:10.1055/s-2007-979312 · Cited by 49
Benzodiazepines and the Psychopathology of Catatonia
Ungvari, G. S., Leung, H. C. M., & Lee, T. (1994) · Pharmacopsychiatry · doi:10.1055/s-2007-1014312 · Cited by 49
Suzuki, T., Uchida, H., Watanabe, K., Nakajima, S., Nomura, K., Takeuchi, H., Tanabe, A., Yagi, G., & Kashima, H. (2008) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.959 · Cited by 49
Determining the optimal dose of haloperidol in first-episode psychosis
Oosthuizen, P., Emsley, R. A., Turner, J., & Keyter, N. (2001) · Journal of Psychopharmacology · doi:10.1177/026988110101500403 · Cited by 48 · cited 1×
“…schizophrenia patients in randomized and open trials and such doses were not inferior to higher doses of haloperidol (Kahn et al. 2008; Keefe et al. 2004, 2006; Lieberman et al. 2003b; Moller et al. 2008; Oosthuizen et al. 2004; Oosthuizen et al. 2001; Remington et al. 1998; Schooler et al. 2005).”
ZIMBROFF, D. L., Warrington, L. E., Loebel, A. D., Yang, R., & SIU, C. O. (2007) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32816f7779 · Cited by 48
Rettenbacher, M. A., Hofer, A., Ebenbichler, C. F., Baumgartner, S., Edlinger, M., Engl, J., Kaser, S., Kemmler, G., Malík, P., Tschoner, A., et al. (2010) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181faf0e3 · Cited by 47
Azorin, J., Strub, N., & Loft, H. (2005) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000177020.26311.a7 · Cited by 47
Ziprasidone and the Corrected QT Interval
Camm, A. J., Karayal, O. N., Meltzer, H. Y., Kolluri, S., O’Gorman, C., Miceli, J. J., Tensfeldt, T. G., & Kane, J. M. (2012) · CNS Drugs · doi:10.2165/11599010-000000000-00000 · Cited by 46
Benzodiazepine augmentation of neuroleptics in treatment-resistant schizophrenia.
Wolkowitz, O. M., Turetsky, N., Reus, V. I., & Hargreaves, W. A. (1992) · PubMed · Cited by 46
Glick, I. D., Bosch, J., & Casey, D. E. (2009) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181a443d0 · Cited by 46
Thioridazine and chlordiazepoxide, alone and combined, in the treatment of chronic schizophrenia
Holden, J., Itil, T. M., Keskiner, A., & Fixk, M. (1968) · Comprehensive Psychiatry · doi:10.1016/s0010-440x(68)80059-8 · Cited by 46
Treatment Strategies for Dosing the Second Generation Antipsychotics
Schwartz, T. L., & Stahl, S. M. (2011) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2011.00234.x · Cited by 45
Clinical and economic ramifications of switching antipsychotics in the treatment of schizophrenia
Faries, D. E., Ascher‐Svanum, H., Nyhuis, A. W., & Kinon, B. J. (2009) · BMC Psychiatry · doi:10.1186/1471-244x-9-54 · Cited by 45
The Acute Efficacy of Aripiprazole Across the Symptom Spectrum of Schizophrenia
Janicak, P. G., Glick, I. D., Marder, S. R., et al. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04310 · Cited by 45
Kane, J. M., CRANDALL, D. T., Marcus, R. N., Eudicone, J. M., Pikalov, A., Carson, W. H., & Swyzen, W. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2007.05.009 · Cited by 43
Wagstaff, A. J., Easton, J., & Scott, L. J. (2005) · CNS Drugs · doi:10.2165/00023210-200519020-00005 · Cited by 43
Sacchetti, E., Galluzzo, A., Valsecchi, P., Romeo, F., Gorini, B., & Warrington, L. E. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2009.05.002 · Cited by 43
Interpreting the Efficacy Findings in the CATIE Study: What Clinicians Should Know
Meltzer, H. Y., & Bobo, W. V. (2006) · CNS Spectrums · doi:10.1017/s109285290002664x · Cited by 42
Lévy-Rueff, M., Gourévitch, R., Löo, H., Olié, J., & Amado, I. (2010) · Psychiatry Research · doi:10.1016/j.psychres.2008.10.012 · Cited by 42
Kane, J. M., Potkin, S. G., Daniel, D. G., & Buckley, P. F. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.07m03733yel · Cited by 42
Xiang, Y., Wang, C., Si, T., Lee, E. H. M., He, Y.-L., Ungvari, G. S., Chiu, H. F. K., Shinfuku, N., Yang, S., Chong, M., et al. (2011) · Australian & New Zealand Journal of Psychiatry · doi:10.3109/00048674.2011.607426 · Cited by 42
Enquête de pratiques de prescription des antipsychotiques dans 13 centres hospitaliers du réseau PIC
Bret, P., Bret, M.-C., & Queuille, E. (2008) · L Encéphale · doi:10.1016/j.encep.2008.03.007 · Cited by 42
Hahn, M., Remington, G. J., Bois, D., & Cohn, T. A. (2010) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181fab67d · Cited by 41
The effect of quetiapine on aggression and hostility in patients with schizophrenia
Arango, C., & Bernardo, M. (2005) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.686 · Cited by 41
Kristensen, D., Bauer, J., Hageman, I., & Jørgensen, M. B. (2010) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-010-0173-3 · Cited by 41
Augmentation With Pregabalin in Schizophrenia
Englisch, S., Eer, A., Enning, F., Hohmann, S., Schanz, H., & Zink, M. (2010) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181e5c095 · Cited by 40
Bobes, J., Gibert, J., Ciudad, A., Álvarez, E., Cañas, F., Carrasco, J.-L., Gascón, J., Gómez, J., & Gutiérrez, M. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(03)00035-6 · Cited by 40
Benzodiazepines for catatonia in people with schizophrenia and other serious mental illnesses
Gibson, R. C., & Walcott, G. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006570.pub2 · Cited by 40
Do effectiveness (“real world”) studies on antipsychotics tell us the real truth?
Möller, H. (2008) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-008-0812-0 · Cited by 39
Self-citationComparative effects of fluphenazine, fluphenazine-chlordiazepoxide and fluphenazine-imipramine.
Hanlon, T. E., Ky, O., & KURLAND, A. A. (1970) · PubMed · Cited by 39
Akter, K. A., Gallo, D., Martin, S. A., Myronyuk, N., Roberts, R. T., Stercula, K., & Raffa, R. B. (2011) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2011.01265.x · Cited by 38
Citrome, L. (2012) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2011.02890.x · Cited by 38
Möller, H. J., Riedel, M. J., Müller, N., Fischer, W., & Kohnen, R. (2004) · Pharmacopsychiatry · doi:10.1055/s-2004-832683 · Cited by 38
Self-citationFriedman, J. I., Lindenmayer, J., Alcantara, F., Bowler, S., Parak, M., WHITE, L. E., Iskander, A., Parrella, M. J., Adler, D. N., Tsopelas, N. D., et al. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.14 · Cited by 38
Lindenmayer, J., Citrome, L., Khan, A., Kaushik, S., & Kaushik, S. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31820f4fe0 · Cited by 37
Sherwood, M., Thornton, A. E., & Honer, W. G. (2005) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145705005961 · Cited by 36
Ganguli, R., Brar, J. S., Mahmoud, R. A., Berry, S. A., & Pandina, G. (2008) · BMC Medicine · doi:10.1186/1741-7015-6-17 · Cited by 35
Schlösser, R. G. M., Gründer, G., Anghelescu, I. G., Hillert, A., Ewald-Gründer, S., Hiemke, C., & Benkert, O. (2002) · Neuropsychobiology · doi:10.1159/000063574 · Cited by 35
Neuroleptic malignant syndrome and serotonin syndrome
Nisijima, K., Shioda, K., & Iwamura, T. (2007) · Progress in brain research · doi:10.1016/s0079-6123(06)62006-2 · Cited by 34
Hwang, T., Lee, S.-M., Sun, H., Lin, H.-N., Tsai, S., Lee, Y.-C., & Chen, Y.-S. (2003) · PubMed · Cited by 34
Risperidone dose for schizophrenia
Li, C., Xia, J., & Wang, J. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007474.pub2 · Cited by 33
Adjunctive imipramine for a broader group of post-psychotic depressions in schizophrenia
Siris, S. G., Pollack, S. Z., Bermanzohn, P. C., & Stronger, R. (2000) · Schizophrenia Research · doi:10.1016/s0920-9964(99)00197-8 · Cited by 33
Takeuchi, H., Suzuki, T., Uchida, H., Nakajima, S., Nomura, K., Kikuchi, T., Manki, H., Watanabe, K., & Kashima, H. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181842586 · Cited by 33
Beta-Blocker Supplementation of Standard Drug Treatment for Schizophrenia
Shek, E., Bardhan, S., Cheine, M. V., Ahonen, J., & Wahlbeck, K. (2010) · Schizophrenia Bulletin · doi:10.1093/schbul/sbq089 · Cited by 33
Patrick, D. L., Burns, T., Morosini, P., Gagnon, D. D., Rothman, M., & Adriaenssen, I. (2010) · Clinical Therapeutics · doi:10.1016/j.clinthera.2010.02.003 · Cited by 32 · cited 1×
“…iloperidone, asenapine, lurasidone) in comparison to placebo (Canuso et al. 2009a,b; Citrome 2009; Cutler et al. 2008; Davidson et al. 2007; Kane et al. 2007a, 2011a; Marder et al. 2007a; Meltzer et al. 2008a; Nakamura et al. 2009; Nussbaum and Stroup 2008; Patrick et al. 2010; Potkin et al. 2007).”
BackgroundJeste, D. V., Klausner, M. A., Brecher, M., Clyde, C., & Jones, R. (1997) · Psychopharmacology · doi:10.1007/s002130050289 · Cited by 32
How to grade categories of evidence
Bandelow, B., Zohar, J., Kasper, S. F., & Möller, H. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970802456590 · Cited by 32
Self-citationLamotrigine-Clozapine Combination in Refractory Schizophrenia: Three Cases
Saba, G., Dumortier, G., Kalalou, K., Benadhira, R., Degrassat, K., Glikman, J., & Januel, D. (2002) · Journal of Neuropsychiatry · doi:10.1176/jnp.14.1.86 · Cited by 32
Effects of antipsychotics on cognitive performance in drug-naive schizophrenic patients
Lee, S.-M., Chou, Y.-H., Li, M., Wan, F.-J., & Yen, M. (2007) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.03.016 · Cited by 31
Intramuscular Aripiprazole in the Control of Agitation
Currier, G. W., Citrome, L., ZIMBROFF, D. L., Oren, D. A., MANOS, G., McQuade, R. D., PIKALOV, A. A., & CRANDALL, D. T. (2007) · Journal of Psychiatric Practice · doi:10.1097/01.pra.0000271657.09717.e2 · Cited by 30
Clonazepam/haloperidol combination therapy in schizophrenia: A double blind study
Altamura, A. C., Mauri, M. C., Mantero, M., & Brunetti, M. (1987) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1987.tb02942.x · Cited by 30
Klieser, E., Strauß, W. H., & Lemmer, W. (1994) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1994.tb05836.x · Cited by 30
Short-Term Inpatient Pharmacotherapy of Schizophrenia
Osser, D. N., & Sigadel, R. (2001) · Harvard Review of Psychiatry · doi:10.1080/10673220127892 · Cited by 30
High-Dose Treatment With Haloperidol: The Effect of Dose Reduction
Volavka, J., Cooper, T. B., Czobor, P., Lindenmayer, J., Citrome, L., Mohr, P., & Bark, N. M. (2000) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200004000-00020 · Cited by 29
Combination Therapy in the Treatment of Schizophrenia
Wolff‐Menzler, C., Hasan, A., Malchow, B., Falkai, P., & Wobrock, T. (2010) · Pharmacopsychiatry · doi:10.1055/s-0030-1249097 · Cited by 29
Self-citationKelly, D. L., Conley, R. R., Love, R. C., Morrison, J. A., & McMahon, R. P. (2008) · Annals of Clinical Psychiatry · doi:10.1080/10401230802017050 · Cited by 29
Sanford, M., & Scott, L. J. (2008) · CNS Drugs · doi:10.2165/00023210-200822040-00005 · Cited by 29
Effect of topiramate augmentation in chronic schizophrenia: a placebo-controlled trial.
Behdani, F., Hebrani, P., Ardanı, A. R., & Rafee, E. (2011) · PubMed · Cited by 29
Müller, M. J., Wetzel, H., Eich, F. X., Rein, W., Puech, A. J., & Benkert, O. (2002) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200212000-00004 · Cited by 29
Stahl, S. M., MALLA, A. K., Newcomer, J. W., Potkin, S. G., Weiden, P. J., Harvey, P. D., Loebel, A. D., Watsky, E. J., SIU, C. O., & Romano, S. (2010) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181e69042 · Cited by 28
Wolf, J., Janssen, F., Lublin, H., Salokangas, R. K. R., Allain, H., Smeraldi, E., Bernardo, M., Millar, H. L., Pans, M., Adelbrecht, C., et al. (2007) · Current Medical Research and Opinion · doi:10.1185/030079907x225448 · Cited by 28
DeSilva, P., Fenton, M., & Rathbone, J. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001948.pub2 · Cited by 27
Kasper, S. F., Lowry, A. J., Hodge, A. T., et al. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.07.032 · Cited by 27
Gafoor, R., Landau, S., Craig, T., Elanjithara, T., Power, P., & McGuire, P. K. (2010) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181f198da · Cited by 27
Ryckmans, V., Kahn, J., Modell, S., Werner, C., McQuade, R., Kerselaers, W., Lissens, J., & Sanchez, R. (2009) · Pharmacopsychiatry · doi:10.1055/s-0028-1112134 · Cited by 27
Daniel, D. G., Currier, G. W., ZIMBROFF, D. L., ALLEN, M. H., Oren, D. A., MANOS, G., McQuade, R. D., PIKALOV, A. A., & CRANDALL, D. T. (2007) · Journal of Psychiatric Practice · doi:10.1097/01.pra.0000271658.86845.81 · Cited by 27
Henderson, D. C., Fan, X., Copeland, P. M., Sharma, B., Borba, C. P. C., Forstbauer, S., Miley, K. M., Boxill, R., Freudenreich, O., Cather, C., et al. (2009) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.1012 · Cited by 26
Crocq, M. A., Набер, Д., LADER, M. H., Thibaut, F., Drici, M., Everitt, B. J., Hall, G. C., Jeunne, C. L., Mittoux, A., Peuskens, J., et al. (2010) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2010.09.001 · Cited by 26
Self-citationTreatment with amisulpride and olanzapine improve neuropsychological function in schizophrenia
Mortimer, A. M., Joyce, E. M., Balasubramaniam, K., Choudhary, P. C., & Saleem, P. (2007) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.865 · Cited by 26
Canuso, C. M., Bossie, C. A., Turkoz, I., & Alphs, L. D. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2009.05.021 · Cited by 25
Castle, D. J., Udristoiu, T., Kim, C. Y., Sárosi, A., Pidrman, V., Omar, A. N., Rosales, J. I., Melamed, Y., Isik, T., Karagianis, J. L., et al. (2009) · The World Journal of Biological Psychiatry · doi:10.1080/15622970802688051 · Cited by 24
Long-Term Efficacy and Tolerability of Clozapine Combined with Ziprasidone or Risperidone
Kuwilsky, A., Krumm, B., Englisch, S., Dreßing, H. R., & Zink, M. (2010) · Pharmacopsychiatry · doi:10.1055/s-0030-1254089 · Cited by 24
Cordes, J., Falkai, P., Guse, B., Hasan, A., Schneider-Axmann, T., Arends, M., Winterer, G., Wölwer, W., Sliman, E. B., Ramacher, M., et al. (2009) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-009-0060-y · Cited by 24
Self-citationChiu, N., Yang, Y. K., Chen, P. S., Chang, C., Lee, I. H., & Lee, J. (2003) · Psychiatry and Clinical Neurosciences · doi:10.1046/j.1440-1819.2003.01151.x · Cited by 24
Rémillard, S., Pourcher, E., & Cohen, H. (2007) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617708080090 · Cited by 23
Kim, C. Y., Chung, S., Lee, J.-N., Kwon, J. S., Kim, D., Kim, C. E., Jeong, B., Jeon, Y., Lee, M.-S., Jun, T., et al. (2009) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32832c25d7 · Cited by 22
Chakos, M., Patel, J., Rosenheck, R. A., Glick, I. D., Hamner, M. B., Miller, D. D., Tapp, A. M., & Miller, A. L. (2011) · Clinical Schizophrenia & Related Psychoses · doi:10.3371/csrp.5.3.2 · Cited by 22
Sacchetti, E., Valsecchi, P., & Parrinello, G. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2007.09.011 · Cited by 22
Simpson, G. M., O'Gorman, C. J., Loebel, A. D., & Yang, R. (2008) · CNS Spectrums · doi:10.1017/s1092852900017004 · Cited by 22
Adjunctive Carbamazepine or Lithium Carbonate in Therapy-Resistant Chronic Schizophrenia
Simhandl, C., Meszaros, K., Denk, E., Thau, K., & Topitz, A. (1996) · The Canadian Journal of Psychiatry · doi:10.1177/070674379604100513 · Cited by 22
Aripiprazole versus typicals for schizophrenia
Bhattacharjee, J., & El-Sayeh, H. G. G. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006617.pub2 · Cited by 21
Hwang, T., Lin, S., & Lin, H.-N. (2001) · PubMed · Cited by 21
Álvarez, E., Bobes, J., Gómez, J.-C., Sacristán, J. A., Cañas, F., Carrasco, J. L., Gascón, J., Gibert, J., & Gutiérrez, M. (2002) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(02)00079-2 · Cited by 20
Clozapine and Ziprasidone: A Useful Combination in Patients With Treatment-Resistant Schizophrenia
Ziegenbein, M., & Calliess, I. T. (2006) · Journal of Neuropsychiatry · doi:10.1176/appi.neuropsych.18.2.246 · Cited by 20
Andersen, R., Fagerlund, B., Rasmussen, H., Ebdrup, B. H., Aggernæs, B., Gade, A., Oranje, B., & Glenthoj, B. Y. (2010) · Psychiatry Research · doi:10.1016/j.psychres.2010.10.013 · Cited by 20
Self-citationGlick, I. D., Lemmens, P., & Vester-Blokland, E. (2001) · International Clinical Psychopharmacology · doi:10.1097/00004850-200109000-00003 · Cited by 19
Olanzapine Versus Risperidone in Newly Admitted Acutely Ill Psychotic Patients
Kraus, J. E., Sheitman, B., Cook, A., Reviere, R., & Lieberman, J. A. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n1211 · Cited by 19
Self-citationQuetiapine in schizophrenia: onset of action within the first week of treatment
Small, J. G., Kolar, M. C., & Kellams, J. J. (2004) · Current Medical Research and Opinion · doi:10.1185/030079904125004033 · Cited by 19
Bhowmick, S., Hazra, A., & Ghosh, M. (2010) · Australian & New Zealand Journal of Psychiatry · doi:10.3109/00048670903487134 · Cited by 19
Ziprasidone in Treatment-Resistant Schizophrenia
Loebel, A. D., Khanna, S., Rajadhyaksha, S., SIU, C. O., Giller, E. L., & Potkin, S. G. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0902 · Cited by 18
Trial of aripiprazole in the treatment of first‐episode schizophrenia
Lee, H., Ham, B., Kang, R.-H., Paik, J., Hahn, S., Lee, M., & Lee, M. (2010) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.2009.02039.x · Cited by 18
Switching to amisulpride monotherapy for treatment-resistant schizophrenia
Kontaxakis, V. P., Havaki-Kontaxaki, B. J., Ferentinos, P. P., Paplos, K. G., & Soldatos, C. R. (2006) · European Psychiatry · doi:10.1016/j.eurpsy.2006.01.013 · Cited by 18
Docherty, J. P., Baker, R. A., Eudicone, J. M., Mathew, S., Marcus, R. N., McQuade, R. D., & Mankoski, R. E. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.03.040 · Cited by 18
Comparative utility of aripiprazole and haloperidol in schizophrenia
Kane, J. M., Kim, E., Kan, H. J., Guo, Z., Bates, J. A., Whitehead, R. E., & Pikalov, A. (2009) · Applied Health Economics and Health Policy · doi:10.1007/bf03256145 · Cited by 17
Stip, É., Zhornitsky, S., Potvin, S., & Tourjman, V. (2010) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.05.010 · Cited by 17
Initial Improvement as a Criterion for Drug Choice in Acute Schizophrenia
Klimke, A., Klieser, E., Lehmann, E., & Miele, L. (1993) · Pharmacopsychiatry · doi:10.1055/s-2007-1014337 · Cited by 17
Altamura, A. C., Velonà, I., Curreli, R., Mundo, E., & Bravi, D. (2002) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/136515002753724117 · Cited by 17
Olanzapine: a review of rapid and long-acting parenteral formulations
Owen, R. T. (2010) · Drugs of today · doi:10.1358/dot.2010.46.3.1476499 · Cited by 16
Efficacy and Tolerability of Aripiprazole in First-Episode Drug-Naive Patients With Schizophrenia
Takahashi, H., Oshimo, T., & Ishigooka, J. (2009) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e31817c6b06 · Cited by 16
Clinical Advantages of Amisulpride in the Treatment of Acute Schizophrenia
Burns, T., & Bale, R. (2001) · Journal of International Medical Research · doi:10.1177/147323000102900601 · Cited by 16
Faries, D. E., Ascher‐Svanum, H., Nyhuis, A. W., & Kinon, B. J. (2008) · Current Medical Research and Opinion · doi:10.1185/030079908x297385 · Cited by 15
Ciudad, A., Gutiérrez, M., Cañas, F., Gibert, J., Gascón, J., Carrasco, J.-L., Bobes, J., Gómez, J., & Álvarez, E. (2005) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2005.04.037 · Cited by 15
Zotepine versus other atypical antipsychotics for schizophrenia
Subramanian, S., Rummel‐Kluge, C., Hunger, H., Schmid, F., Schwarz, S., Kissling, W., Leucht, S., & Komossa, K. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006628.pub3 · Cited by 15
Epileptische Anfälle unter der Behandlung mit Antidepressiva und Neuroleptika
Steinert, T., Baier, H., Fröscher, W., et al. (2010) · Fortschritte der Neurologie · Psychiatrie · doi:10.1055/s-0029-1245704 · Cited by 15
Pérez, V., Cañas, F., & Tafalla, M. (2008) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e3282f47c44 · Cited by 14
Long-Term Lamotrigine Adjunctive to Antipsychotic Monotherapy in Schizophrenia: Further Evidence
Kolivakis, T., Beauclair, L., Margolese, H. C., & Chouinard, G. (2004) · The Canadian Journal of Psychiatry · doi:10.1177/070674370404900411 · Cited by 14
Pajonk, F., Schreiner, A., Peters, S., Rettig, K., Degner, D., & Rüther, E. (2005) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000170686.27476.ab · Cited by 12
Understanding the Results of CATIE in the Context of the Field
Glick, I. D. (2006) · CNS Spectrums · doi:10.1017/s1092852900026675 · Cited by 12
Sertindole for the treatment of schizophrenia
Azorin, J., Kaladjian, A., Fakra, É., & Adida, M. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2010.536217 · Cited by 11
Kane, J. M., Assunção-Talbott, S., Eudicone, J. M., Pikalov, A., Whitehead, R. E., & CRANDALL, D. T. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.06.018 · Cited by 11
Schwarz, C. J., Hartung, B., & Leucht, S. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003083.pub2 · Cited by 10
Risperidone Versus Placebo for Schizophrenia
Rattehalli, R., Jayaram, M., & Smith, M. (2010) · Schizophrenia Bulletin · doi:10.1093/schbul/sbq030 · Cited by 10
Dose–response relationship of sertindole and haloperidol using the pharmacopsychometric triangle
Bech, P., Tanghøj, P., Andreasson, K., & Overø, K. F. (2010) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2010.01581.x · Cited by 7
Carrasco, J. L., Guti??rrez, M., ́mez, J. C. G., Escobar, R., ́lvarez, E. A., as, F. C., Bobes, J., Gasc??n, J., & Gibert, J. (2002) · International Clinical Psychopharmacology · doi:10.1097/00004850-200211000-00004 · Cited by 6
Defining and characterising treatment-resistant schizophrenia
Marder, S. R. (1995) · European Psychiatry · doi:10.1016/0767-399x(96)80078-2 · Cited by 6
Lancelin, F., Bourcier, E., Masson, V. D., Lemeille, Y., Brovedani, S., Paubel, P., & Piketty, M. (2010) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e3181fa57fe · Cited by 5
Pharmacotherapy of fi rst-episode schizophrenia
Kudva, Y. C., & Montori, V. M. (2008) · Cited by 3
Cited by
Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Örey, D., Richter, F., Samara, M., Barbui, C., Engel, R. R., Geddes, J. R., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60733-3 · Cited by 2,561
Galletly, C., Castle, D., Dark, F., Humberstone, V., Jablensky, A., Killackey, E., Kulkarni, J., McGorry, P., Nielssen, O., & Tran, N. (2016) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867416641195 · Cited by 877
Barnes, T. R., Drake, R., Paton, C., Cooper, S. J., Deakin, B., Ferrier, I. N., Gregory, C. J., Haddad, P. M., Howes, O. D., Jones, I., et al. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881119889296 · Cited by 606
Hasan, A., Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W. F., Thibaut, F., Möller, H.-J., & WFSBP Task force on Treatment Guidelines for Schizophrenia (2013) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2012.739708 · Cited by 416
Self-citationThe impact of environmental factors in severe psychiatric disorders
Schmitt, A., Malchow, B., Hasan, A., & Falkai, P. (2014) · Frontiers in Neuroscience · doi:10.3389/fnins.2014.00019 · Cited by 322
Self-citation
Metadata
- Authors
- Hasan, A., Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W. F., Thibaut, F., Möller, H.-J., & the Wfsbp Task Force on Treatment Guidelines for Schizophrenia
- Venue
- The World Journal of Biological Psychiatry
- Publisher
- Informa UK Limited
- Published
- 2012-07
- Volume
- 13
- Issue
- 5
- Pages
- 318-378
- ISSN
- 1562-2975 (ISSN-L)
- 1814-1412
- OpenAlex
- W2157369969
- Cited by
- 637
- References
- 529
- FWCI
- 22.54
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.